Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
Eur Rev Med Pharmacol Sci. 2023 Oct;27(19):9375-9387. doi: 10.26355/eurrev_202310_33965.
The objective of the current study was to investigate the cytotoxic potentials of Galactosylated Chitosan Nanoparticles. Specifically, the study aimed to develop Tubermycin B coated on Galactosylated Chitosan Nanoparticles using a new green method that replaces sodium borohydride in the reduction process.
The study synthesized Tubermycin B coated on Galactosylated Chitosan Nanoparticles through a new green method. The cytotoxicity of these nanoparticles was evaluated in a mice intestinal tract model that had been induced with chlorpyrifos, which causes oxidative stress-related enterotoxicity. Multiple activities, including the apoptosis of intestinal macrophages and the activation of Ikappa α/β kinase (IKKα/β), were examined as indicators of the nanoparticles' efficacy. The stability of the synthesized Chitosan Nanoparticles was also assessed. Additionally, the encapsulation efficiency of Boscia angustifalia and Boscia senegalensis extracts within the nanoparticles was determined.
The results of the study showed that Tubermycin B coated on Galactosylated Chitosan Nanoparticles effectively alleviated the oxidative stress-related enterotoxicity in the mice intestinal tract induced by chlorpyrifos. The nanoparticles prevented the apoptosis of intestinal macrophages and inhibited the activation of IKKα/β. The synthesized chitosan nanoparticles exhibited high stability. The encapsulation efficiency of Boscia angustifalia extract was recorded as 46.58%, whereas for Boscia senegalensis extract, it was 9.77%. The nanoparticles showed no cytotoxicity at all tested concentrations and demonstrated a medium-level anticancer effect.
Based on the findings, it can be concluded that Tubermycin B coated on Galactosylated Chitosan Nanoparticles has the potential to alleviate oxidative stress-related enterotoxicity in the mice intestinal tract. The nanoparticles showed high stability and exhibited a medium-level anticancer effect. Furthermore, the study demonstrated that Boscia angustifalia extract exhibited higher anti-hepatitis C virus antibodies (anti-HCV) activity compared to Boscia senegalensis extract in an in-vitro system. Therefore, Boscia angustifalia could be considered a promising candidate for the development of an anti-HCV drug for future in-vivo studies.
本研究旨在探讨半乳糖化壳聚糖纳米粒子的细胞毒性潜力。具体而言，本研究旨在开发一种新的绿色方法，用该方法替代还原过程中的硼氢化钠，将 Tubermycin B 包被到半乳糖化壳聚糖纳米粒子上。
本研究通过一种新的绿色方法合成了 Tubermycin B 包被的半乳糖化壳聚糖纳米粒子。通过氯吡磷诱导的小鼠肠道模型评估了这些纳米粒子的细胞毒性，该模型可引起氧化应激相关肠毒性。作为纳米粒子疗效的指标，检测了肠道巨噬细胞凋亡和 Ikappa α/β 激酶 (IKKα/β) 的激活等多种活性。还评估了合成的壳聚糖纳米粒子的稳定性。此外，还测定了纳米粒子中 Boscia angustifalia 和 Boscia senegalensis 提取物的包封效率。
研究结果表明，Tubermycin B 包被的半乳糖化壳聚糖纳米粒子可有效缓解氯吡磷诱导的小鼠肠道氧化应激相关肠毒性。纳米粒子阻止了肠道巨噬细胞的凋亡并抑制了 IKKα/β 的激活。合成的壳聚糖纳米粒子表现出高稳定性。Boscia angustifalia 提取物的包封效率为 46.58%，而 Boscia senegalensis 提取物的包封效率为 9.77%。在所有测试浓度下，纳米粒子均无细胞毒性，表现出中等水平的抗癌作用。
基于研究结果，可以得出结论，Tubermycin B 包被的半乳糖化壳聚糖纳米粒子具有缓解小鼠肠道氧化应激相关肠毒性的潜力。纳米粒子表现出高稳定性，并表现出中等水平的抗癌作用。此外，研究表明，在体外系统中，Boscia angustifalia 提取物比 Boscia senegalensis 提取物具有更高的抗丙型肝炎病毒抗体（抗 HCV）活性。因此，Boscia angustifalia 可被视为开发抗 HCV 药物的有前途的候选药物，以供未来的体内研究。
